Genetics & Longevity Variants

The ACE insertion/deletion (I/D) polymorphism (rs4646994) involves a 287-bp Alu repeat in intron 16 of the angiotensin-converting enzyme gene; the D allele is associated with approximately 1.5–2 times the serum ACE activity of the II genotype, influencing the renin-angiotensin-aldosterone system and thereby blood pressure regulation and cardiovascular tone. Early studies reported associations between the D allele and myocardial infarction risk, and between the I allele and elite endurance performance, though many of these findings have not replicated consistently in larger studies or meta-analyses. In the context of longevity, associations have been reported in several centenarian cohorts but the direction and magnitude are inconsistent across populations. The ACE I/D locus is best understood as a modest modulator of ACE enzyme levels with population-specific effects, rather than a robust longevity locus.

The APOE ε4 allele encodes apolipoprotein E isoform E4, which differs from the ε3 isoform at residue 112 (cysteine→arginine), altering lipoprotein binding preferences and reducing efficient clearance of triglyceride-rich remnants and LDL from circulation. In the brain, E4 impairs amyloid-β clearance via the blood-brain barrier and through astrocytic and microglial processing, promotes tau pathology, and potentiates neuroinflammation via microglial activation — effects partly independent of amyloid. The allele confers dose-dependent Alzheimer's disease risk: one ε4 copy increases risk approximately 3–4-fold, two copies approximately 8–12-fold in European populations, with risk magnitudes varying across ancestries. Despite its disease associations, the ε4 allele has been maintained at ~14% global allele frequency, likely reflecting ancient trade-offs involving immune function, fertility, and early cognitive performance.

ATM (ataxia-telangiectasia mutated) encodes a serine/threonine protein kinase that is the master activator of the DNA damage response to double-strand breaks; upon activation it phosphorylates hundreds of substrates including H2AX, CHK2, p53, and BRCA1 to coordinate cell-cycle arrest, DNA repair, and apoptosis. Biallelic loss-of-function mutations cause ataxia-telangiectasia, a recessive syndrome characterized by cerebellar neurodegeneration, immunodeficiency, radiation sensitivity, and a cancer risk exceeding 30%. Heterozygous ATM carriers (~1% of the population) have intermediate cancer risk — particularly for breast and colorectal cancer — and recent data suggest moderately elevated cardiovascular disease risk, placing ATM among the clinically actionable cancer-predisposition genes. In longevity biology, compromised ATM function exemplifies how defects in the DNA damage response accelerate hallmarks of aging including genomic instability and inflammation.

Cholesteryl ester transfer protein (CETP) mediates the exchange of cholesteryl esters from HDL for triglycerides in VLDL and LDL, effectively lowering HDL-cholesterol. The I405V variant (rs5882) in the CETP gene reduces CETP activity and is enriched in Ashkenazi Jewish centenarians and their offspring relative to controls in the Einstein Aging Study (Barzilai et al., 2003), accompanying notably high HDL and large HDL particle size. Large HDL particles are more effective in reverse cholesterol transport and are associated with reduced cardiovascular and cognitive disease risk. The variant illustrates how a naturally occurring loss-of-function polymorphism can phenocopy the cardiovascular benefit sought by pharmacological CETP inhibitors, several of which failed in trials despite HDL elevation — suggesting particle quality over quantity matters.

FOXO3 encodes a forkhead-box transcription factor that integrates signals from the insulin/IGF-1 and AMPK pathways to regulate stress resistance, autophagy, apoptosis, and antioxidant gene expression. A cluster of intronic single-nucleotide polymorphisms — most prominently rs2802292 — was first associated with exceptional longevity in Hawaiian men of Japanese ancestry (Willcox et al., 2008) and has since been replicated across multiple independent cohorts in Europe, East Asia, and Ashkenazi populations. The protective allele is thought to promote nuclear retention of FOXO3, enhancing expression of downstream targets including GADD45, SOD2, and autophagy regulators. Because FOXO3 sits at the convergence of multiple conserved longevity pathways, it remains one of the most consistently replicated genetic associations with human lifespan.

A genome-wide association study (GWAS) is an agnostic scan of common single-nucleotide polymorphisms (SNPs, typically minor allele frequency >1–5%) across the genome to identify loci statistically associated with a trait or disease, using a stringent significance threshold of p<5×10⁻⁸ to control for multiple testing of ~1 million tag SNPs in linkage disequilibrium (LD) with surrounding variants. GWAS operates on the common-disease/common-variant hypothesis and is optimized for polygenic traits; most discovered variants have modest individual effect sizes (OR 1.05–1.3), requiring very large sample sizes (tens to hundreds of thousands) to detect reliably. In longevity, GWAS findings are relatively sparse: the APOE locus (particularly ε2 protection and ε4 risk) is by far the strongest and most replicated hit for exceptional longevity; other candidates including FOXO3, TOMM40/APOC1, and CDKN2B-AS1 are supported by some studies but lack universal replication. The modest GWAS yield for longevity likely reflects its heterogeneous, polygenic, and late-acting genetic architecture.

The KL-VS haplotype of the klotho gene (comprising variants F352V and C370S in exon 2) increases serum klotho protein levels and is associated with longevity in heterozygous but not homozygous carriers — a pattern consistent with heterozygote advantage. Heterozygous KL-VS carriers show elevated circulating klotho and, in several studies, improved cognitive function and reduced dementia risk, with functional MRI data suggesting enhanced prefrontal connectivity (Dubal et al., 2014; Yokoyama et al., 2015). The variant also associates with favorable cardiovascular and bone mineral density profiles in some cohorts. Mechanistically, higher serum klotho is thought to enhance FGF23 co-receptor signaling, modulate Wnt and IGF-1 pathways, and exert neuroprotective effects independently of its endocrine roles.

LMNA encodes the nuclear lamina proteins Lamin A and Lamin C through alternative splicing; the lamins form a filamentous meshwork underlying the inner nuclear membrane that provides mechanical support and organizes peripheral chromatin, influencing gene expression, DNA repair, and nuclear shape. A de novo C→T transition at position 1824 (c.1824C>T; G608G) in exon 11 activates a cryptic splice site, producing a truncated and permanently farnesylated Lamin A isoform called progerin, which causes Hutchinson-Gilford Progeria Syndrome (HGPS) — a devastating childhood progeroid syndrome with accelerated cardiovascular disease and a median survival of approximately 14 years. Importantly, low levels of the same aberrant splice product accumulate in normal aging cells even without the HGPS mutation, and nuclear lamina integrity declines broadly with age, suggesting LMNA biology has relevance beyond the rare syndrome. Lonafarnib (Zokinvy), a farnesyltransferase inhibitor that blocks progerin farnesylation, received FDA approval in November 2020 for HGPS and extends median survival by approximately 2.5 years; additional progerin-targeting approaches are in early investigation.

Mitochondrial haplogroups are clusters of maternally inherited mitochondrial DNA (mtDNA) haplotypes defined by shared polymorphisms, reflecting ancient migration patterns and geographic lineages. Because mtDNA encodes 13 essential respiratory-chain subunits and 22 tRNAs, haplogroup-defining variants can subtly alter oxidative phosphorylation efficiency, reactive oxygen species production, and mitochondrial morphology. Several studies have reported associations between specific haplogroups and longevity, most notably sub-haplogroups D4a and D5 among Japanese centenarians (Tanaka et al.), and haplogroup J in some European centenarian cohorts; however, replication across populations is inconsistent, sample sizes in the original studies were modest, and population stratification is a persistent confound. Mitochondrial haplogroups therefore represent plausible but not firmly established modulators of aging trajectory.

The C677T polymorphism (rs1801133) in methylenetetrahydrofolate reductase (MTHFR) encodes a thermolabile enzyme with reduced activity (approximately 70–75% reduction in TT homozygotes — retaining only ~25–30% residual activity — and ~35% reduction in CT heterozygotes, particularly under low-folate conditions) and causes modest elevation of plasma homocysteine. Elevated homocysteine has been epidemiologically associated with cardiovascular disease and neural tube defects, and the variant is correspondingly associated with those outcomes, though the causal role of homocysteine itself remains debated. The clinical relevance of MTHFR C677T genotyping is contested: major laboratory and genetics societies advise against routine population testing, noting that the association is modest, diet-modifiable, and that homocysteine-lowering B-vitamin supplementation has not consistently reduced cardiovascular events in trials. Despite its limited clinical actionability, it remains one of the most over-ordered genetic tests in functional medicine contexts.

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a serine protease secreted by hepatocytes that binds to the LDL receptor on the cell surface and directs it to lysosomal degradation rather than recycling, thereby reducing LDL uptake and raising circulating LDL-cholesterol. Rare gain-of-function PCSK9 mutations cause familial hypercholesterolaemia, while loss-of-function variants — particularly prevalent in African-American cohorts (e.g., Y142X, C679X) — produce lifelong very low LDL levels and markedly reduced coronary heart disease risk without adverse phenotypes, validating the target. Monoclonal antibodies against PCSK9 (alirocumab, evolocumab) reduce LDL by 50–60% on top of statin therapy and lower cardiovascular event rates in high-risk patients; inclisiran, a small-interfering RNA targeting PCSK9 mRNA in hepatocytes, achieves similar LDL lowering with twice-yearly dosing.

Pharmacogenomics studies how genetic variation — primarily in drug-metabolizing enzymes, transporters, and drug targets — influences individual drug response in terms of efficacy and toxicity. CYP2C9 and VKORC1 variants are the canonical example for warfarin dosing: poor metabolizers at CYP2C9 combined with VKORC1 low-expression haplotypes require markedly lower doses to achieve therapeutic anticoagulation, and dosing algorithms incorporating genotype reduce bleeding events. For statins, a non-synonymous variant in SLCO1B1 (rs4149056, Val174Ala) reduces hepatic uptake of simvastatin and atorvastatin, raising plasma drug levels and increasing myopathy risk several-fold in CC homozygotes. Pharmacogenomics is particularly relevant to older adults with polypharmacy because drug-drug-gene interactions compound with age-related changes in kidney and liver function; clinical implementation through pre-emptive panel genotyping is expanding, with CPIC guidelines providing evidence-based dose recommendations for over 40 drug-gene pairs.

A polygenic risk score (PRS) is a weighted sum of an individual's risk-allele dosages across many SNPs associated with a trait, with weights typically derived from GWAS summary statistics using methods such as LD-pruning and thresholding (P+T) or Bayesian shrinkage (LDpred, PRSice). For common complex diseases — including coronary artery disease, type 2 diabetes, and breast cancer — high PRS identifies individuals with lifetime risk comparable to monogenic mutation carriers, suggesting clinical utility for stratified prevention. However, PRS performance degrades substantially when applied across ancestry groups because GWAS discovery cohorts have been disproportionately European, and LD patterns and allele frequencies differ between populations, limiting equitable deployment. Additional challenges include calibration drift over time, limited ability to capture rare variants and gene-environment interactions, and conceptual questions about whether PRS for longevity traits represents a useful clinical endpoint given their composite, late-acting nature.

Sirtuins are NAD⁺-dependent deacylases and ADP-ribosyltransferases; the three most studied longevity-relevant isoforms differ sharply in subcellular compartment and substrate specificity. SIRT1 is predominantly nuclear and cytosolic, deacetylating transcriptional regulators including p53, NF-κB, PGC-1α, and FOXO proteins to coordinate metabolism, stress response, and genome maintenance. SIRT3 localizes to the mitochondrial matrix, where its best-characterized substrates include SOD2 (K68; activating antioxidant defence) and components of the electron transport chain, directly linking NAD⁺ status to mitochondrial redox homeostasis. SIRT6 is a nuclear chromatin-associated sirtuin that removes H3K9ac and H3K56ac marks at sites of DNA damage and telomeres, and promotes genomic stability; overexpression of SIRT6 extends lifespan in male mice, and it was later shown to modulate IGF signalling and inflammation.

TERT (telomerase reverse transcriptase) and TERC (telomerase RNA component) together constitute the catalytic core of telomerase; TERT provides reverse-transcriptase activity while TERC is the RNA template used to extend telomeric TTAGGG repeats. Common single-nucleotide variants in both loci are among the strongest GWAS hits for leukocyte telomere length and modestly influence disease risk for cancer, cardiovascular disease, and pulmonary fibrosis in proportion to their effect on telomere length. Rare heterozygous loss-of-function mutations in TERT or TERC cause autosomal dominant telomere biology disorders (TBDs) — a spectrum including dyskeratosis congenita, familial idiopathic pulmonary fibrosis, aplastic anemia, and hepatic cirrhosis — via telomere-mediated replicative failure in high-turnover tissues and anticipation across generations. The contrast between the modest effects of common variants and the severe phenotypes of rare pathogenic mutations illustrates the quantitative sensitivity of telomere homeostasis.

Whole-genome sequencing (WGS) generates complete base-pair-resolution data across nuclear and mitochondrial DNA, enabling discovery of rare coding and non-coding variants, structural variants, and copy-number changes that are invisible to SNP arrays. In aging research, WGS has several distinct applications: it identifies rare longevity-associated variants in centenarian families and cohorts (e.g., protective mutations in PCSK9, APOC3, or DNA repair genes) that require deep sequencing to detect; it quantifies somatic mutation burden and clonal hematopoiesis of indeterminate potential (CHIP) in aging tissues, linking somatic evolution to cardiovascular and cancer risk; and it maps mitochondrial heteroplasmy dynamics that accumulate with age. Sequencing costs have fallen from ~$3,000/Gb in 2008 toward approximately $1–5/Gb by the mid-2020s depending on platform and throughput, making population-scale WGS studies feasible; however, interpreting variants of uncertain significance (VUS) and managing incidental findings remain major clinical and ethical challenges, especially as WGS enters preventive medicine for healthy aging populations.

WRN encodes a member of the RecQ DNA helicase family with both helicase and exonuclease activities, involved in multiple DNA repair pathways including base excision repair, non-homologous end joining, and replication fork restart at sites of stalled polymerases. Biallelic loss-of-function mutations cause Werner syndrome, a segmental progeroid syndrome in which features of aging — including cataracts, atherosclerosis, type 2 diabetes, osteoporosis, and malignancies — appear in the third and fourth decades; median survival historically has been approximately 46 years, though a 2022 retrospective study found mean age at death had risen to approximately 59 years, likely reflecting improved management of malignancy and vascular disease. At the cellular level, WRN-deficient cells accumulate replication stress, telomere dysfunction, and genomic instability disproportionately rapidly. Werner syndrome is extensively studied as a model of accelerated aging, particularly to distinguish aging-driver from aging-bystander mechanisms, though the segmental nature of the phenotype means it does not recapitulate normal aging comprehensively.